Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03193359

Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

A Multicenter, Open-label, Safety, Tolerability and Efficacy Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Allergan · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study is an open-label extension study to evaluate the safety, tolerability and efficacy of BOTOX® as headache prophylaxis in Chinese patients with chronic migraine who have successfully completed the double-blind study: 1313-301-008.

Conditions

Interventions

TypeNameDescription
BIOLOGICALbotulinum toxin Type ABotulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.

Timeline

Start date
2018-01-15
Primary completion
2021-09-09
Completion
2021-09-09
First posted
2017-06-20
Last updated
2017-07-14

Source: ClinicalTrials.gov record NCT03193359. Inclusion in this directory is not an endorsement.

Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine (NCT03193359) · Clinical Trials Directory